Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes

Inclusion Criteria: 1. Age ≥18-79 years at the time of STEMI diagnosis 2. Diagnosed with ST-segment elevation myocardial infarction (STEMI) based on standard clinical criteria 3. Received antiplatelet therapy as part of STEMI management 4. Underwent primary percutaneous coronary intervention (PCI) 5. Evidence of hemorrhagic MI confirmed by Cardiac Magnetic Resonance Imaging OR Post-PCI biomarker diagnostics 6. Availability of comprehensive medical records documenting STEMI presentation, treatment details, and clinical outcomes 7. Minimum of 30-day follow-up data, with extended follow-up available for up to 10 years Exclusion Criteria: 1. Diagnosis of non-STEMI (NSTEMI), unstable angina, or other non-ischemic cardiomyopathies 2. History of prior hemorrhagic stroke or active intracranial bleeding before the index STEMI event 3. Known bleeding disorders (e.g., hemophilia, thrombocytopenia \<50,000/µL) 4. Use of chronic antiplatelet therapy (aspirin, clopidogrel, ticagrelor, prasugrel) before STEMI diagnosis 5. Use of long-term anticoagulation therapy (warfarin, DOACs such as apixaban, rivaroxaban, dabigatran) before STEMI diagnosis 6. Incomplete or missing medical records preventing outcome assessment 7. History of malignancy with life expectancy \<1 year at the time of STEMI diagnosis 8. Patients lost to follow-up before 30 days post-STEMI